Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial

医学 心房颤动 阿哌沙班 改良兰金量表 冲程(发动机) 人口 临床终点 华法林 内科学 拜瑞妥 随机对照试验 外科 缺血性中风 环境卫生 机械工程 缺血 工程类
作者
Floris H.B.M. Schreuder,Koen M. van Nieuwenhuizen,Jeannette Hofmeijer,Sarah E. Vermeer,Henk Kerkhoff,Elles Zock,Gert Jan Luijckx,Gert Messchendorp,Julia H. van Tuijl,Henri Paul Bienfait,Suzanne J. Booij,Ido R. van den Wijngaard,Michel J. M. Remmers,Antonia H. C. M. L. Schreuder,Diederik W.J. Dippel,Julie Staals,Paul J.A.M. Brouwers,Marieke J.H. Wermer,Jonathan M. Coutinho,Vincent I.H. Kwa
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:20 (11): 907-916 被引量:124
标识
DOI:10.1016/s1474-4422(21)00298-2
摘要

BACKGROUND: In patients with atrial fibrillation who survive an anticoagulation-associated intracerebral haemorrhage, a decision must be made as to whether restarting or permanently avoiding anticoagulation is the best long-term strategy to prevent recurrent stroke and other vascular events. In APACHE-AF, we aimed to estimate the rates of non-fatal stroke or vascular death in such patients when treated with apixaban compared with when anticoagulation was avoided, to inform the design of a larger trial. METHODS: -VASc score of at least 2 and a score on the modified Rankin scale (mRS) of 4 or less. Participants were randomly assigned (1:1) to receive oral apixaban (5 mg twice daily or a reduced dose of 2·5 mg twice daily) or to avoid anticoagulation (oral antiplatelet agents could be prescribed at the discretion of the treating physician) by a central computerised randomisation system, stratified by the intention to start or withhold antiplatelet therapy in participants randomised to avoiding anticoagulation, and minimised for age and intracerebral haemorrhage location. The primary outcome was a composite of non-fatal stroke or vascular death, whichever came first, during a minimum follow-up of 6 months, analysed using Cox proportional hazards modelling in the intention-to-treat population. APACHE-AF is registered with ClinicalTrials.gov (NCT02565693) and the Netherlands Trial Register (NL4395), and the trial is closed to enrolment at all participating sites. FINDINGS: Between Jan 15, 2015, and July 6, 2020, we recruited 101 patients (median age 78 years [IQR 73-83]; 55 [54%] were men and 46 [46%] were women; 100 [99%] were White and one [1%] was Black) a median of 46 days (IQR 21-74) after intracerebral haemorrhage. 50 were assigned to apixaban and 51 to avoid anticoagulation (of whom 26 [51%] started antiplatelet therapy). None were lost to follow-up. Over a median follow-up of 1·9 years (IQR 1·0-3·1; 222 person-years), non-fatal stroke or vascular death occurred in 13 (26%) participants allocated to apixaban (annual event rate 12·6% [95% CI 6·7-21·5]) and in 12 (24%) allocated to avoid anticoagulation (11·9% [95% CI 6·2-20·8]; adjusted hazard ratio 1·05 [95% CI 0·48-2·31]; p=0·90). Serious adverse events that were not outcome events occurred in 29 (58%) of 50 participants assigned to apixaban and 29 (57%) of 51 assigned to avoid anticoagulation. INTERPRETATION: Patients with atrial fibrillation who had an intracerebral haemorrhage while taking anticoagulants have a high subsequent annual risk of non-fatal stroke or vascular death, whether allocated to apixaban or to avoid anticoagulation. Our data underline the need for randomised controlled trials large enough to allow identification of subgroups in whom restarting anticoagulation might be either beneficial or hazardous. FUNDING: Dutch Heart Foundation (grant 2012T077).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
Grace发布了新的文献求助10
3秒前
3秒前
可爱的函函的应助被pkubest采纳,获得10
4秒前
4秒前
阳光奎发布了新的文献求助10
4秒前
orixero的应助被尉迟姿采纳,获得10
4秒前
1900发布了新的文献求助10
5秒前
6秒前
6秒前
情怀的应助被ddiou采纳,获得10
7秒前
8秒前
小姜同学完成签到,获得积分10
8秒前
柚溪发布了新的文献求助10
9秒前
ccyao完成签到,获得积分20
9秒前
9秒前
10秒前
小蘑菇的应助被雷瑞采纳,获得10
10秒前
11秒前
alex完成签到,获得积分10
11秒前
JunfDai发布了新的文献求助10
11秒前
ccyao发布了新的文献求助10
11秒前
13秒前
14秒前
心灵美的花生完成签到,获得积分10
14秒前
小姜同学发布了新的文献求助10
14秒前
15秒前
pp009900发布了新的文献求助10
15秒前
16秒前
17秒前
YMM完成签到,获得积分10
18秒前
pkubest发布了新的文献求助10
18秒前
邓巧发布了新的文献求助10
20秒前
SciGPT的应助被杰_骜不驯采纳,获得10
20秒前
20秒前
山住一完成签到,获得积分10
20秒前
健忘豌豆发布了新的文献求助10
20秒前
20秒前
小强发布了新的文献求助10
20秒前
戊戌发布了新的文献求助10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177767
求助须知:如何正确求助?哪些是违规求助? 9568590
关于积分的说明 21799821
捐赠科研通 7772374
什么是DOI,文献DOI怎么找? 3432476
关于科研通互助平台的介绍 2556695
邀请新用户注册赠送积分活动 2478034